Loading stock data…
Ironwood Pharmaceuticals, Inc. (IRWD)
$4.30+0.17 (+4.12%)
Market ClosedLast close Jun 29
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ironwood Pharmaceuticals, Inc. in the Healthcare sector is trading at $4.30 with a market capitalization of $533M. Wall Street consensus targets $6.10 (4 analysts), implying a +41.9% move over the next 12 months. The stock is currently 26% below its 52-week high of $5.78, remaining 28.4% above its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +41.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $106.51M↑ | $47.71M↓ | $122.06M↑ | $85.24M↑ | $41.14M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $72.53M↑ | $6.55M↓ | $77.68M↑ | $45.07M↑ | -$10.55M |
| Net Income | $40.77M↑ | -$2.28M↓ | $40.08M↑ | $23.60M↑ | -$37.39M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase typ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$533.35M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
5.23
Beta
Defensive asset. Lower volatility than the S&P 500.
0.30
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-47.05%
Volume
Today's trading volume
3.47M
Recent News
Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Invest in Amid a Biotech Comeback
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Can Linzess Continue Driving IRWD's Revenue Growth Through 2026?
Ironwood sees Linzess momentum as strong demand, a pediatric expansion and pricing changes are expected to boost revenues and profit in 2026.
Is Ironwood Pharmaceuticals, Inc. (IRWD) Strengthening Its Growth Outlook With Expanded Pediatric Approval for Linzess?
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is one of the most undervalued stocks to invest in. TheFly reported on May 27 that IRWD reported that the U.S. Food and Drug Administration expanded the approved use of Linzess to include pediatric patients as young […]
Is Ironwood Pharmaceuticals, Inc. (IRWD) a Comeback Pharma Stock After Major Earnings Improvement?
We recently compiled a list of the 8 Best Small Cap Pharma Stocks to Buy Right Now. Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is among the best small cap pharma stocks. TheFly reported on May 7 that IRWD reported its first-quarter 2026 financial performance for the period ended March 31, 2026, showing great year-over-year improvement. Total revenue […]